As we busily analyze field data collected from our annual IDN survey, we would like to offer a sneak peek at how oncology pharmacists want to engage with manufacturers in 2022 and beyond.
COVID-19 changed numerous aspects of the healthcare engagement experience. Virtual health, virtual learning and virtual meetings have become a part of daily operations. As hospitals and providers slowly return to a new normal, we wondered how providers may want to interact with manufacturer personnel going forward.
We asked 100+ oncology pharmacists to design their "optimal" manufacturer engagement experience by allocating points across 3 channels: in-person meetings, virtual meetings / presentations, and independent online research.
1. Almost all oncology pharmacists included some portion of in-person meetings in their optimal engagement mix. In-person meetings provide “interesting” interactions and networking opportunities.
2. However, the desire to continue virtual meetings/webinars is clear, with an average of 40% of their time allocated to this channel. According to respondents, virtual meetings or presentations are “effective”, “efficient” and “easier to fit into my schedule.”
3. Additionally, multiple oncology pharmacists suggest real-time Q&A capabilities on manufacturers’ sites are helpful additions during online information searches
For more information on IDN decision making, clinical controls and manufacturer engagement opportunities, stay tuned for our IDN Annual Survey Trend Report in mid-May.
As always, please reach out with any comments or questions you have.
All the best...
-- HMP Market Access Insights Team
Welcome to the March 2023 edition of our Monthly Insight Series. This month we discuss how Humana terminated its employer group line of business and the implications.Chris Van Denburg
We want to give you a look at some of the topics we’re planning to explore this year, as we enter yet another period of rapid change, upheaval, and uncertainty in 2023-2025.Lee Blansett
Welcome to the February 2023 edition of our Monthly Insight Series. This month we discuss how community oncology providers are engaging in value-based care.Taylor Crutison, Lee Blansett, Nandini Jha